Resolaris: Phase Ib/II started

aTyr began an open-label, placebo-controlled, intra-patient dose-escalation, international Phase Ib/II trial to evaluate 0.3, 1 and 3 mg/kg IV Resolaris once weekly for 12 weeks in up to 16 patients. ...